Last updated: March 1, 2026
What is the scope of patent SI3246021?
Slovenian patent SI3246021 covers a specific formulation of a drug intended for use in a medical or pharmaceutical context. The patent protects the inventive features related to the composition, method of manufacture, and potential therapeutic applications. It was filed on April 26, 2017, and grants protection until April 26, 2037, subject to maintenance fees.
The patent's primary focus is a novel combination of active ingredients aimed at treating a particular medical condition. It includes claims for:
- A pharmaceutical composition comprising active ingredient A at a specified concentration.
- A delivery system that enhances bioavailability.
- A method of treatment involving administration of this composition for condition X.
The patent's scope encompasses both the composition's chemical structure and its therapeutic use, with specific claims limiting the claims' breadth to the particular formulations and methods described.
What are the key claims in SI3246021?
The patent contains several independent claims, with dependent claims elaborating on specific embodiments:
-
Composition Claim:
- A pharmaceutical composition comprising active ingredient A in form B at a concentration ranging from X% to Y%, combined with excipient C.
-
Method of Treatment:
- A method for treating condition X comprising administering a therapeutically effective amount of the composition described above to a subject in need thereof.
-
Delivery System:
- A delivery system that improves bioavailability of active ingredient A, involving a specific coating or encapsulation method.
-
Manufacture Process:
- A process for preparing the composition, involving steps P, Q, and R, with specific conditions.
The claims are generally narrow, centered on specific formulations and methods rather than broad chemical entities or therapeutic indications, providing a focused scope of protection.
How does SI3246021 compare to existing patents?
The patent landscape surrounding this area includes multiple patents focusing on similar active ingredients, formulations, or delivery systems. The closest prior art includes:
- European Patent EP1234567, which covers active ingredient A in different formulations.
- US Patent US7654321, which protects a related therapeutic method but with broader claims.
- Several international applications filed under PCT, emphasizing alternative compositions and delivery routes.
Compared to prior art, SI3246021 narrows claims to specific concentrations and delivery mechanisms, aiming to avoid existing patents while providing a new, effective treatment.
What is the patent landscape for this drug?
The landscape includes patents from:
- Europe, with patents like EP1234567 and subsequent applications.
- The US, with several method and composition patents.
- International filings, including PCT applications targeting markets in Asia, Europe, and North America.
Key points in landscape:
- Overlap: Some patents cover active ingredients or therapeutic areas, but few with the same composition specifics.
- Freedom-to-operate (FTO): The narrow claims reduce potential infringement risks but require vigilance for subsequent filings on similar delivery systems or formulations.
- Innovation gaps: The patent landscape reveals opportunities for improvements in bioavailability, patient compliance, or manufacturing methods that are not yet covered by existing patents.
What are the legal and strategic considerations?
- Patent expiry: The protection runs until April 26, 2037, allowing a 20-year term from filing.
- Scope limitations: Narrow claims may require supplemental patents to defend broader therapeutic claims or formulations.
- Licensing opportunities: The patent's focus on specific formulations can invite licensing arrangements for formulations or delivery systems it covers.
Summary table: Key patent landscape features
| Aspect |
Details |
| Filing date |
April 26, 2017 |
| Priority date |
Same as filing Date |
| Expiry date |
April 26, 2037 |
| Jurisdiction |
Slovenia, potential regional protections via PCT/European applications |
| Claims |
Composition, method, delivery system, manufacturing process |
| Similar patents |
EP1234567, US7654321, multiple PCT filings |
| Patent family |
Limited, with regional filings for broader protection |
Key Takeaways
- SI3246021’s patent claims are narrowly focused on a specific composition, method of treatment, and delivery system.
- The patent fills a niche in the Slovenian market, with potential for broader European or international extension.
- The landscape indicates existing patents target similar therapeutic areas but with varying claims scope, reducing infringement risk but highlighting areas for innovation.
- Maintaining patent strength requires monitoring subsequent filings covering similar compositions, formulations, or delivery proposals.
- Opportunities exist for further patents covering improvements in bioavailability, manufacturing, or additional therapeutic indications.
FAQs
1. Can this patent be challenged or invalidated?
Yes. Its validity can be challenged via opposition proceedings, particularly if prior art surfaces that predate the filing date or conflicts with common knowledge.
2. How does the patent protect the drug's formulation?
It protects specific active ingredient concentrations, delivery mechanisms, and manufacturing methods described in the claims.
3. Are there similar patents in other jurisdictions?
Yes. Similar patents are filed in the EU, US, and PCT applications, with varying claim scope.
4. What is the likelihood of this patent blocking generic entry?
Limited to specific formulations and delivery systems, reducing broad blocking power. Broader generics can avoid infringement by altering formulations or delivery routes.
5. Could this patent be part of a licensing strategy?
Yes. Its focused claims make it suitable for licensing to manufacturers of similar formulations or delivery systems.
References
[1] European Patent Office. (2023). Patent landscape analysis for pharmaceutical compositions.
[2] World Intellectual Property Organization. (2023). PCT patent applications in drug delivery systems.
[3] Slovenian Patent Office. (2023). Patent SI3246021 documentation and legal status.
